[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"inflammatory-bowel-disease-ulcerative-colitis-type\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:inflammatory-bowel-disease-ulcerative-colitis-type":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,48],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":30,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100650890","evaluation-of-the-effects-of-colipral-on-microbiota-gut-composition-in-patients-presenting-with-ulcerative-colitis-during-remission-phase-and-functional-disorders-100650890",false,"NCT07751081","Evaluation of the Effects of Colipral on Microbiota Gut Composition in Patients Presenting With Ulcerative Colitis During Remission Phase and Functional Disorders","Evaluation of the Effects of Colipral® (E.Coli 5C LMG S-33222) on Microbiota Gut Composition in Patients Presenting With Ulcerative Colitis During Remission Phase and Functional Disorders","COLIPRAL","Inclusion criteria:\n\n* Diagnosis of UC confirmed by clinical, endoscopic and histopathological evidence.\n* Disease in remission phase confirmed by clinical, endoscopic and histopathological evidence for at least 6 months\n* Diagnosis of disorders of gut-brain interaction (DGBI): IBS-D, IBS-M, bloating, and abdominal pain\n* Male\u002Ffemale\n* Age in the range 18-70 years\n* Subjects capable of conforming to the study protocol\n* Subjects who have given their free and informed consent\n\nExclusion criteria:\n\n* History of gastrointestinal disorders or gastrointestinal surgery interfering with gastrointestinal function\n* Subjects with untreated food intolerance, i.e. remaining symptomatic despite the withdrawal of the suspected food\n* Currently following a restrictive diet (for example low FODMAPs diet or vegan diet)\n* Females of childbearing potential, in the absence of effective contraceptive methods\n* Subjects who become unable to conform to protocol\n* Recent history or suspicion of alcohol abuse or drug addiction\n* Indication for the initiation of a new drug therapy during the study\n* History of current or recent antibiotic or probiotics use within the last 30 days\n* Subjects who are treated with antibiotics","ALL","18 Years","70 Years",{"count":21,"type":22},50,"ESTIMATED","INTERVENTIONAL",[25],"NA","The study is a double-blind, placebo-controlled, crossover, randomised trial, in which enrolled subjects will be included for 18 months. This study aims to evaluate the effect of the Colipral as a Food Supplement prescribed according to the standard of care of patients suffering UC during remission phase and DGBI.\n\nThe primary objective of the study is to evaluate the variation in gut microbiota, specifically focusing on bacterial diversity and abundance, in patients with UC during the remission phase and DGBI.\n\nThe secondary objective of the study is to evaluate the clinical parameters variations (based on fecal calprotectin and IBDQ's score before and after the treatment), the severity of gastrointestinal symptoms, the quality of life, and the maintenance of the remission phase in patients with UC in remission and DGBI.",[28,29],"Inflammatory Bowel Disease, Ulcerative Colitis Type","Functional Disorder of Gastrointestinal Tract",[31,32,33,34],"inflammatory bowel disease","ulcerative colitis","functional disorders","gut microbiota","NOT_YET_RECRUITING","2026-08-03",{"date":38,"type":39},"2026-08-07","ACTUAL",{"date":41,"type":22},"2026-09-01",{"date":43,"type":22},"2028-03",{"name":45,"class":46},"University of Padova","OTHER",1,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":55,"enrollmentInfo":56,"targetDuration":4,"studyType":23,"phases":58,"briefSummary":59,"conditions":60,"keywords":63,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":47},"100461857","intestinal-organoids-100461857","NCT05294107","Intestinal Organoids","BIOÏDES","Inclusion Criteria:\n\n* Subjects aged 18 to 75 years\n* Subject undergoing endoscopy as part of the standard of care with the need to take digestive biopsy samples\n* Subject having signed a free and informed consent in writing\n\nExclusion Criteria:\n\n* Subjects under legal protection (safeguard of justice, curatorship or guardianship) or deprived of liberty.\n* Anticoagulant treatment and anti-platelet treatment (except for aspirin 75 mg)","75 Years",{"count":57,"type":22},90,[25],"Over the last decade, the use of mini-organ or organoids has been increasingly developed in fundamental research. Indeed, digestive organoids represent an essential advance compared to classical culture systems (epithelial cell lines, immortalized cells) since they preserve in culture the functional complexity present in vivo (architecture, different cell types). They also have the advantage of being able to be propagated indefinitely (unlike explants), minimizing the use of animal models and reducing the amount of tissue required. Finally, their growth and development depends on the origin of the sample (the organoid will develop differently if the cell source comes from a patient suffering from an inflammatory bowel disease, for example), thus generating models of human pathologies to better determine their physiopathology. The use of organoids in biomedical research has proven to be an indispensable tool for the understanding of cellular and molecular mechanisms involved in epithelial renewal and the screening of molecules and ingredients for applications in the health and agri-food sectors.",[61,28,62],"Digestive System Diseases","Crohn Disease",[64,65,66,31],"biobank","organoids","digestive disease","RECRUITING","2026-06-15",{"date":70,"type":39},"2026-06-17",{"date":72,"type":39},"2022-09-06",{"date":74,"type":22},"2028-03-07",{"name":76,"class":46},"Rennes University Hospital"]